Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFS | ACET |
|---|---|---|
| Founded | 2001 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 71.3M |
| IPO Year | 2012 | N/A |
| Metric | OFS | ACET |
|---|---|---|
| Price | $4.66 | $8.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 63.5K | ★ 184.4K |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | ★ 13.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $42,970,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $7.15 |
| 52 Week High | $9.80 | $17.44 |
| Indicator | OFS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 42.87 | 64.65 |
| Support Level | $4.91 | $8.18 |
| Resistance Level | $5.01 | $9.00 |
| Average True Range (ATR) | 0.22 | 0.48 |
| MACD | -0.01 | -0.29 |
| Stochastic Oscillator | 6.45 | 16.41 |
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.